Fosfomycin is a legitimate, guideline-recommended antibiotic for uncomplicated urinary tract infections, yet most doctors reach for other options first. The reasons come down to a combination of lower cure rates compared to alternatives, limited approved uses (especially in the United States), and practical concerns about resistance that make it a second-choice drug in most clinical situations despite its unique mechanism.
It Works, but Not as Well as Alternatives
Fosfomycin is officially listed as a first-line option for uncomplicated cystitis alongside nitrofurantoin and trimethoprim-sulfamethoxazole (TMP-SMX) in the 2025 AUA/CUA/SUFU guidelines. On paper, it belongs in the same tier. In practice, the numbers tell a different story.
The cure rate for fosfomycin ranges from 83% to 91%, while nitrofurantoin achieves 88% to 93% and TMP-SMX reaches 90% to 100%. That gap widens in head-to-head trials. A large multinational randomized trial comparing single-dose fosfomycin to a five-day course of nitrofurantoin found clinical resolution of 58% versus 70%, with 28-day microbiological resolution at 63% versus 74%. Treatment failure within the first week was also more common with fosfomycin (8.16% versus 6.87% for nitrofurantoin) in a real-world cohort of over 33,000 patients. One bright spot: reinfection rates between days 8 and 30 were actually lower with fosfomycin (7.76% versus 9.21%), but that advantage doesn’t offset the lower initial cure rate for most prescribers.
When doctors have two first-line drugs that perform better and cost comparably, fosfomycin naturally falls to the back of the rotation.
Severely Limited Approval in the US
For decades, fosfomycin was available in the United States only as an oral formulation approved for one indication: uncomplicated UTIs. That’s it. No complicated infections, no kidney infections, no bloodstream infections. Meanwhile, countries across Europe and parts of Asia have used both oral and intravenous formulations for a much wider range of infections.
The FDA did eventually approve an IV version (branded as Contepo) for complicated urinary tract infections including acute pyelonephritis, but the clinical trial supporting that approval enrolled 99% of its patients in Eastern Europe. This limited geographic footprint in the trial data, combined with decades of US clinicians having no access to IV fosfomycin, means the drug simply never became part of the prescribing culture in American medicine. Physicians tend to prescribe what they trained with, and most US-trained doctors have little experience with fosfomycin beyond the occasional single-dose sachet for a straightforward bladder infection.
The Single-Dose Problem
Fosfomycin’s most appealing feature, a one-time 3-gram dose for uncomplicated cystitis, is also one of its weaknesses. A single dose is convenient for the patient, but it means fosfomycin gets one shot at clearing the infection. If it doesn’t work, you’ve lost time and still need to start a different antibiotic. By contrast, a five-day course of nitrofurantoin or a three-day course of TMP-SMX maintains drug levels in the urinary tract over multiple days, giving the immune system more sustained support.
This trade-off between convenience and effectiveness is a real consideration. For a patient who is unlikely to complete a multi-day course, single-dose fosfomycin has clear value. But for routine prescribing where adherence isn’t a major concern, the drugs with longer courses and higher cure rates tend to win out.
Rising Resistance Is a Growing Worry
Fosfomycin resistance has historically been low, which is one reason guidelines still include it. But that picture is changing in concerning ways. A study of urinary tract E. coli isolates in children found resistance in 38.5% of samples, a strikingly high number driven largely by resistance genes (particularly fosA3 and fosA) that bacteria can share with each other through mobile genetic elements.
This matters because transferable resistance can spread quickly through bacterial populations. Fosfomycin’s mechanism of action is genuinely unique: it permanently disables an enzyme called MurA that catalyzes the very first step in building the bacterial cell wall. No other antibiotic targets this step, which should theoretically make cross-resistance rare. But bacteria have found workarounds through these fos genes, which produce enzymes that chemically inactivate the drug before it can reach its target. The more fosfomycin is used, the more selective pressure favors bacteria carrying these genes.
Current resistance rates vary widely by region and population. In many adult populations, resistance remains under 5%, which is why guidelines still list it as a viable option. But the pediatric data and reports from certain geographic areas suggest that broad, routine use could accelerate resistance in a drug that’s valued precisely because resistance has been low.
Its Real Niche: Drug-Resistant Infections
Where fosfomycin genuinely shines is against multidrug-resistant bacteria. The 2025 AUA/SUFU guidelines note that fosfomycin covers vancomycin-resistant enterococci and extended-spectrum beta-lactamase producing gram-negative bacteria, two categories of resistant organisms that most oral antibiotics can’t touch. It also causes minimal “collateral damage,” meaning it’s less likely to disrupt your normal gut bacteria or promote resistance in other species compared to broader-spectrum antibiotics.
This is the role most infectious disease specialists envision for fosfomycin: a reserve agent for UTIs caused by bacteria that have already developed resistance to the usual drugs. Using it routinely for every uncomplicated UTI would erode its effectiveness against these harder-to-treat infections, which gives prescribers another reason to hold it back.
Side Effects Are Mild but Add Context
Fosfomycin is generally well tolerated. Diarrhea is the most common side effect, occurring in roughly 10% of patients. Nausea, abdominal pain, and indigestion each occur in 1% to 10% of cases. These numbers are comparable to other UTI antibiotics and aren’t a major reason fosfomycin is underused. But they do mean there’s no tolerability advantage that would push it ahead of alternatives with better cure rates.
The overall picture is an antibiotic that works through a one-of-a-kind mechanism, is convenient to take, and causes few problems, but consistently underperforms the competition in clinical trials. Combined with limited US approval history, narrow indications, and a strategic desire to preserve its effectiveness against resistant organisms, fosfomycin ends up as the antibiotic doctors know about but rarely reach for first.